Potassium Binder Eased Dietary Restriction Burden in Dialysis Trial

Trial Evaluates Potassium Binder to Relieve Dietary Burden

Adding the potassium binder sodium zirconium cyclosilicate (SZC) to nutrition counseling reduced the daily burden of dietary potassium restrictions in individuals on maintenance hemodialysis. Investigators presented the clinical trial findings at the American Society of Nephrology (ASN) Kidney Week 2026 conference.

Managing hyperkalemia, or elevated blood potassium, is a regular requirement during hemodialysis care that often forces strict food limits. The eight-week trial evaluated whether medical potassium binding could safely ease those limits while keeping blood levels controlled.

Trial Design and Key Patient Outcomes

The multicenter, randomized, open-label, parallel-group study evaluated outpatients who received maintenance hemodialysis three times per week. Each participant entered the trial with a pre-dialysis serum potassium level between 5.5 and less than 6.5 milliequivalents per liter (mEq/L).

Investigators assigned participants to receive either SZC alongside standardized nutritional counseling or nutritional counseling alone. In the primary analysis of 183 patients, participants given SZC experienced a greater improvement in diet-related quality of life than the counseling-only group.

• Participants receiving SZC experienced more effective lowering of pre-dialysis serum potassium than participants receiving nutritional counseling alone.
• Zero patients in the SZC group required rescue treatment during the eight-week study period.
• Twenty-five of 92 patients in the control group required rescue treatment for elevated potassium levels.
• The trial recorded no serious treatment-related adverse events or participant deaths.

Exploratory Findings on Fruit Intake and Daily Life

Exploratory analyses showed that patients in the SZC group increased their fruit intake without raising their total dietary potassium intake. The investigators also observed measurable gains across several general domains of kidney disease-related quality of life.

Corresponding author Hiromichi Wakui, M.D., Ph.D., of Yokohama City University Graduate School of Medicine, stated that treatment should be judged both by potassium levels and by whether therapy makes daily life less burdensome. The findings suggest that medication can support daily nutrition rather than relying entirely on strict food avoidance.

Practical Context and Study Limitations

The trial authors emphasized that regular potassium monitoring and individualized nutritional assessments remain necessary components of care. Potassium-binding therapy does not eliminate the need to track dietary intake or evaluate kidney function closely.

The study followed participants for eight weeks under an open-label design, meaning patients and clinicians knew their assigned treatments. Longer studies are needed to determine whether these quality-of-life gains persist over extended dialysis treatment. Individuals managing kidney health should discuss any dietary changes or medication options directly with their nephrologist.